Self-Emulsifying Composition for Lopinavir Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV-related cervical dysplasia, especially in low-resource settings, lack effective, inexpensive, and non-surgical options with minimal side effects, and existing formulations for lopinavir and ritonavir have limitations in stability and bioavailability.
Innovation Solution
A self-emulsifying pharmaceutical composition comprising an unsaturated free fatty acid, at least two emulsifiers with specific HLB values, and lopinavir and ritonavir, which allows for improved bioavailability and stability, enabling topical or oral administration for treating HPV-related conditions with reduced emulsifier content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If vegetable oils and polysorbates are used as emulsifiers in SEDDS formulations, then the formulation can be manufactured, but the free fatty acid composition varies from batch to batch and over time, affecting quality consistency
Solution Approach 1:
The patent extracts and isolates specific free fatty acids (oleic acid, linoleic acid, alpha-linolenic acid) from complex vegetable oil matrices. By using purified individual fatty acids rather than crude vegetable oils, the formulation achieves consistent quality while maintaining ease of manufacture. The specific extraction and selection of these fatty acids eliminates batch-to-batch variability inherent in natural vegetable oils.
Solution Approach 2:
The patent changes the chemical composition parameters by specifying exact fatty acid types and ratios (oleic acid, linoleic acid, alpha-linolenic acid in controlled proportions). This parameter specification transforms the variable natural vegetable oil into a consistent, controllable formulation ingredient, resolving the contradiction between manufacturability and composition stability.
2Quantity of substance
If heat above room temperature is applied to solubilize the active pharmaceutical ingredient, then solubility is improved, but degradation by oxidation and hydrolysis increases
Solution Approach 1:
The patent changes the formulation parameters by selecting specific unsaturated free fatty acids with appropriate solubilizing properties that can dissolve lopinavir at room temperature. This parameter optimization eliminates the need for heat application, thereby preventing thermal-induced oxidation and hydrolysis degradation while achieving adequate drug solubility.
Solution Approach 2:
The unsaturated free fatty acids act as intermediary solubilizing agents that mediate between the lipophilic lopinavir and the aqueous environment. These fatty acids provide a solubilizing medium that works at room temperature, avoiding the need for heat while still achieving adequate drug dissolution through their amphiphilic properties.
3Stability of the object's composition
If high total emulsifier content (30-60% by weight) is used in SEDDS, then stable emulsions are formed, but the formulation complexity and cost increase
Solution Approach 1:
The patent creates a composite emulsion system using a combination of specific unsaturated free fatty acids (oleic acid, linoleic acid, alpha-linolenic acid) in optimized ratios. This composite approach provides synergistic emulsifying properties that achieve stable emulsions at lower total emulsifier concentrations (15-30% by weight) compared to conventional single emulsifier systems, thereby reducing formulation complexity.
Solution Approach 2:
The patent optimizes the emulsifier concentration parameter by demonstrating that stable emulsions can be formed at 15-30% total emulsifier content using the specific fatty acid combination, rather than requiring the conventional 30-60% range. This parameter reduction simplifies the formulation while maintaining emulsion stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides enhanced bioavailability and stability of lopinavir and ritonavir, facilitating effective treatment of HPV-related cervical dysplasia with reduced side effects and improved compliance, particularly in low-resource settings.
Implementation Method 1
the active pharmaceutical ingredient is soluble in the unsaturated free fatty acid and no heat above room temperature is required to achieve solubilisation
Implementation Method 2
When the SEDDS formulation contacts aqueous environments, e.g. in the form of gastrointestinal fluids after oral administration, it spontaneously forms oil-in-water emulsions
Implementation Method 3
Surfactants or emulsifiers are added to ensure efficient self-dispersibility and stability of the formed oil-in-water emulsion
Data Source
AI summary
The present invention relates to self-emulsifying pharmaceutical compositions comprising an unsaturated free fatty acid, at least two emulsifiers and at least one active pharmaceutical ingredient; to the use of said pharmaceutical compositions as a medicament; and to processes for the preparation of said compositions.